News

Similarweb Ltd. Unveils Major Secondary Offering of Shares

Similarweb Ltd. Unveils Major Secondary Offering of Shares

Similarweb Ltd. Launches Notable Secondary Offering

Similarweb Ltd. (“Similarweb”) (NYSE: SMWB), a leading name in digital market intelligence, has kicked off an important underwritten public offering. This offering includes 3,500,000 ordinary shares, made available by a selling shareholder. The goal is to strengthen the market while offering investors a chance to delve into the digital analytics space.

Details of the Offering

The selling shareholder will provide underwriters with a 30-day option to purchase an extra 525,000 ordinary shares at the public offering price, after accounting for underwriting fees and commissions. Importantly, Similarweb will not gain any financial benefits from the sale of these shares.

Underwriters' Role in the Offering

Goldman Sachs & Co. LLC and Barclays are serving as the book-running managers for this strategic initiative. Citizens JMP, William Blair, and Needham & Company are also involved as co-managers, lending strong support to this undertaking.

Registration and Compliance Information

A registration statement on Form F-3, filed under File No. 333-279295, was submitted to the United States Securities and Exchange Commission (SEC) on May 10, 2024. This statement was declared effective on May 31, 2024. It’s noteworthy that the Offering is being carried out under this registration statement. A preliminary prospectus supplement along with the related prospectus that outlines the Offering's terms has been registered with the SEC, ensuring compliance and transparency.

Engagement and Inquiries About the Offering

For those interested, copies of the preliminary prospectus supplement and related documents can be requested at the New York office of Goldman Sachs & Co. LLC or by calling them. Barclays Capital Inc. also offers similar options for obtaining the necessary documentation pertaining to this offering.

About Similarweb

Similarweb delivers essential digital market insights, enabling businesses to excel in competitive landscapes. Through its tools and analytics capabilities, companies can spot opportunities, assess competitive risks, and refine their customer acquisition strategies and revenue generation tactics.

Forward-Looking Statements Explained

This announcement includes forward-looking statements as outlined by relevant laws. These statements reflect the management’s expectations about Similarweb's future, covering areas like product development and market strategies. Terms signifying future events, such as “expect,” “anticipate,” and “may,” indicate these forward-looking statements.

Risks and Uncertainties to Consider

It's crucial to understand that these forward-looking statements are subject to various real-world risks and uncertainties. Numerous known and unknown factors might impact actual outcomes, leading to differences from projected results. Stakeholders should be careful when relying on these statements.

Disclaimer on Offers and Solicitation

This announcement is meant for informational purposes only and does not constitute an offer or solicitation for the purchase or sale of any securities or business interests. Furthermore, offers or sales in certain jurisdictions may be restricted by applicable laws.

Frequently Asked Questions

What is the goal of the secondary offering launched by Similarweb?

The secondary offering's purpose is to provide additional shares for sale, allowing investors to participate in the company's growth within the digital market analytics industry.

Who are the underwriters involved in the Similarweb offering?

The main underwriters for this offering are Goldman Sachs & Co. LLC and Barclays, with co-managers including Citizens JMP, William Blair, and Needham & Company.

How many shares are part of this offering?

This offering consists of 3,500,000 ordinary shares, with an option for underwriters to purchase an additional 525,000 shares.

Will Similarweb benefit financially from this share offering?

No, Similarweb will not receive any proceeds from the selling shareholder's share sale, as this is classified as a secondary offering.

How can I access the preliminary prospectus for this offering?

The preliminary prospectus and additional related documents can be obtained by reaching out to the underwriters or through the SEC’s registration filings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles